common respiratory illness that can cause severe breathing problems, could be approved by August. Pfizer, the maker behind the new RSV vaccine candidate referred to as RSVpreF, announced on Tuesday that the U.S.
Food and Drug Administration had accepted its application for review and has set an action date of deciding whether to approve or not by August 2023. "If approved, RSVpreF would help protect infants at their first breath from the devastating effects of this infectious disease, which though well-known, has been particularly evident throughout this RSV season," Dr.
Annaliesa Anderson, Pfizer’s senior vice president and chief scientific officer of vaccine research and development, said in a statement. "We look forward to progressing the review of Pfizer’s RSV maternal vaccine candidate with the FDA and other regulatory authorities, given its significant potential to positively contribute to global health in the prevention of RSV in infants," Anderson added.RSV, which stands for respiratory syncytial virus, is a common cause of mild cold-like symptoms such as runny nose, cough and fever.
Nearly all U.S. children normally catch an RSV infection by age 2. While everyone can get RSV, it causes the most threat to infants, older adults, and other vulnerable people, who can get serious airway and lung infections, according to the U.S.